Figures & data
Table 1. Characteristics of 60 CML patients with imatinib-resistant
Figure 1. Patients with T315I mutation. (A) T315I mutation was detected by ASO-RT-PCR, as described. In brief, the ASO-RT-PCR protocol amplifies an 863-bp product (both mutant and wild-type alleles and serves as an internal control) and a 304-bp product (when the patient carries the T315I mutation). Lanes 1 and 2: patient A; lanes 3 and 4: patient B; lane 5: patient C; and lane 6: patient D. Lanes 7–10, 11, and 12 show patient with imatinib resistance without mutation, negative control and 100-bp size marker, respectively. (B) Direct sequencing analysis of samples A1, A2, B1, B2, C, and D are shown. As can be seen, the resistant mutated cells expanded from 20% (sample A1) to 90% (sample A2) in patient A and 50% (sample B1) to 60% (sample B2) in patient B. Patient C shows a mix of T315I mutation and wild-type ABL, each %50 and Patient D shows a mix of T315I mutation about %30 and wild-type ABL about %70 in individual samples available.
Table 2. Patient's details with detection of T315I mutation